Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer

Shinichiro Suzuki,Koji Haratani,Hidetoshi Hayashi,Yasutaka Chiba,Junko Tanizaki,Ryoji Kato,Seiichiro Mitani,Yusuke Kawanaka,Takashi Kurosaki,Yoshikazu Hasegawa,Takafumi Okabe,Kaoru Tanaka,Yusaku Akashi,Tomohiro Ozaki,Kazuto Nishio,Akihiko Ito,Kazuhiko Nakagawa

European Journal of Cancer（2022）

引用 6|浏览29

暂无评分

摘要

•The relation of NSCLC tumour burden to PD-1/PD-L1 inhibitor efficacy was evaluated.•High tumour burden (HTB) was associated with resistance to ICI monotherapy.•HTB was not associated with treatment outcomes for cytotoxic chemotherapy.•HTB was associated with macrophage-related and protumourigenic gene expression.•Patients with HTB may require more aggressive treatment than ICI monotherapy.

查看译文

关键词

Non-small-cell lung cancer,Tumour burden,PD-1/PD-L1 inhibitor,Resistance mechanism,M2-type macrophage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要